Compare IDEXX Laboratories, Inc. (IDXX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nvidia Corp — how do they compare? IDEXX Laboratories, Inc. trades at $571.66 (market cap $46.22B), while Nvidia Corp trades at $223.4 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 114× IDEXX Laboratories, Inc.'s market cap, and Nvidia Corp pays a 0.46% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NVDA | |
|---|---|---|
Market Cap | $46.22B | $5.27T |
Sector | Health | Technology |
52-Week High | $766.68 | $235.75 |
52-Week Low | $526.44 | $165.17 |
Enterprise Value | $47.12B | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
NVIDIA (NVDA) trades at $217.56, down 2.86% over the past 24 hours, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.87 exceeding the $1.76 estimate. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97% and robust cash flow from operations of $64.09B. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $325.86.
The outlook for NVDA is favorable, supported by accelerating AI chip demand and a dominant market position. Key opportunities include sustained revenue growth and expanding profitability, while risks involve heightened competition, potential peak AI spending, and market volatility. The stock's current valuation metrics, such as a P/E of 33.31, reflect high growth expectations that must be met to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
